Results 61 to 70 of about 5,314 (201)

Chronic hepatitis in horses with persistent equine hepacivirus infection

Equine Veterinary Journal, Volume 58, Issue 2, Page 444-457, March 2026.
Abstract Background Equine hepacivirus (EqHV) is closely related to hepatitis C virus (HCV), which causes persistent infection and chronic hepatitis in people. Information on persistent EqHV infection and hepatitis is limited. Objectives To report 19 cases of chronic hepatitis and persistent EqHV infection.
Mason C. Jager, Daniela Luethy, Samantha Shallop, Jessica Cathcart, Thomas J. Divers, Jean‐Yin Tan, Erin McConachie Beasley, Philip Johnson, Laurence Leduc, Claire Smith, Camilla Anne Jamieson, K. Gary Magdesian, Gerlinde R. Van de Walle, Joy E. Tomlinson   +13 more
wiley   +1 more source

Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure

Drug Design, Development and Therapy, 2017
Fazia Mir, Alp S Kahveci, Jamal A Ibdah, Veysel Tahan Division of Gastroenterology and Hepatology, University of Missouri, Columbia, MO, USA Abstract: Hepatitis C virus (HCV) is a global pandemic, with nearly 200 million infected patients worldwide ...
Mir F, Kahveci AS, Ibdah JA, Tahan V
doaj  

Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR [PDF]

, 2019
The main targets for neutralizing anti-hepatitis C virus (HCV) antibodies (HCV-nAbs) are the E1 and E2 envelope glycoproteins. We have studied the characteristics of HCV-nAbs through a retrospective study involving 29 HIV/HCV-coinfected patients who ...
Berenguer, Juan, Carrero, Ana, Crespo, Manuel, González García, Juan, Guardional, Josep M., Gómez, Julián, Jiménez Sousa, María Angeles, Martínez, Isidoro, Resino, Salvador, Santos, Ignacio de los, The GESIDA 3603b Cohort Study Group, Vigón, Lorena, Von Wichmann, Miguel A., Vázquez Morón, Sonia, Yélamos, María Belén   +14 more
core   +5 more sources

Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C

Infection and Drug Resistance, 2019
Lindsey M Childs-Kean, Natalie A Brumwell, Emma F LodlDepartment of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Gainesville, FL, USAAbstract: The treatment of chronic hepatitis C has been revolutionized with the
Childs-Kean LM, Brumwell NA, Lodl EF
doaj  

Potential interactions between pangenotypic direct-acting antivirals and concomitant cardiovascular therapies in patients with chronic hepatitis C virus infection

Journal of International Medical Research, 2020
Objective To identify potential drug interactions (DIs) between pangenotypic direct-acting antivirals (pDAAs) and concomitant cardiovascular (CV) therapies in patients with chronic hepatitis C (CHC).
Antoni Sicras-Mainar, Ramón Morillo-Verdugo   +1 more
doaj   +1 more source

Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells

Scientific Reports, 2022
SARS coronavirus 2 (SARS-CoV-2) has caused an ongoing global pandemic with significant mortality and morbidity. At this time, the only FDA-approved therapeutic for COVID-19 is remdesivir, a broad-spectrum antiviral nucleoside analog.
Xammy Huu Wrynla, Eddie Wehri, Erik Van Dis, Scott B. Biering, Livia H. Yamashiro, Chi Zhu, Julien Stroumza, Claire Dugast-Darzacq, Thomas G. W. Graham, Xuanting Wang, Steffen Jockusch, Chuanjuan Tao, Minchen Chien, Wei Xie, Dinshaw J. Patel, Cindy Meyer, Aitor Garzia, Thomas Tuschl, James J. Russo, Jingyue Ju, Anders M. Näär, Sarah Stanley, Julia Schaletzky   +22 more
doaj   +1 more source

Evolución de los pacientes infectados por el virus de la hepatitis C tratados con antivirales de acción directa en Álava. Durante el período 2015-2017. [PDF]

, 2018
[ES] La infección por el virus de la hepatitis C (VHC) en la población general se caracteriza por una evolución crónica y, en general, benigna, tal como demuestran los estudios epidemiológicos prospectivos y retrospectivos.
Gil González, Cristina
core  

Projections of the healthcare costs and disease burden due to hepatitis C infection under different treatment policies in Malaysia, 2018-2040 [PDF]

, 2018
The World Health Organisation (WHO) has set ambitious goals to reduce the global disease burden associated with, and eventually eliminate, viral ...
A Hill, A Thomas, Adeeba Kamarulzaman, Amirah Azzeri, B Devleesschauwer, CJL Murray, D Lunn, EB Tapper, Fatiha Hana Shabaruddin, GJ Dore, J Iversen, JJ Heidelbaugh, Maznah Dahlui, MC Cheung, ME Stouthard, Ministry of Health Malaysia, P Vemer, Rosmawati Mohamed, SA McDonald, SA McDonald, Scott A. McDonald, Seng Gee Lim, Soek S. Tan, SS Tan, The Kirby Institute, TM Welzel, VJ Wirtz, World Health Organisation, World Health Organisation, World Health Organisation   +29 more
core   +1 more source

Bee products as alternatives in the treatment of viral infections

Journal of the Science of Food and Agriculture, Volume 106, Issue 1, Page 33-54, 15 January 2026.
Abstract Medicines used in the treatment of viral infections usually reduce symptoms. There is a need to develop drugs that inhibit the viruses and do not merely relieve the symptoms. Natural bee products possess many pharmacological properties and are widely used in folk medicine. There are many studies on the antibacterial effects of bee products but
Michał Otręba, Łukasz Marek, Jerzy Stojko, Anna Rzepecka‐Stojko   +3 more
wiley   +1 more source

Disrupting Viral Persistence: CRISPR/Cas9‐Based Strategies for Hepatitis B and C Treatment, and Challenges

Journal of Cellular and Molecular Medicine, Volume 30, Issue 1, January 2026.
ABSTRACT Hepatitis B and C viruses (HBV and HCV) remain among the leading causes of liver disease worldwide. Current antiviral drugs, such as nucleotide analogues (NAs), can reduce the replication of new HBV and HCV infections but cannot completely eliminate chronic infections.
Meng‐Fan Li, Akmal Zubair, Safa Wdidi, Shan He   +3 more
wiley   +1 more source